Clinical trials with oncolytic reovirus: Moving beyond phase I into combinations with standard therapeutics

Por Harrington, K.J., Vile, R.G., Melcher, A., Chester, J., Pandha, H.S.
Publicado em 2010

Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity

Por Ilett, EJ, Prestwich, RJ, Kottke, T, Errington, F, Thompson, JM, Harrington, KJ, Pandha, HS, Coffey, M, Selby, PJ, Vile, RG, Melcher, AA
Publicado no Gene Ther (2009)

Tumor infection by oncolytic reovirus primes adaptive anti-tumor immunity

Por Prestwich, RJ, Errington, F, Ilett, EJ, Morgan, R, Scott, K, Kottke, T, Thompson, J, Morrison, EE, Harrington, KJ, Pandha, HS, Selby, PJ, Vile, RG, Melcher, AA
Publicado em 2008

Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma

Por Errington, F, White, CL, Twigger, KR, Rose, A, Scott, K, Steele, L, Ilett, LJ, Prestwich, R, Pandha, HS, Coffey, M, Selby, P, Vile, R, Harrington, KJ, Melcher, AA
Publicado no Gene Ther (2008)

Synergistic cytotoxicity of oncolytic reovirus in combination with cisplatin–paclitaxel doublet chemotherapy

Por Roulstone, V, Twigger, K, Zaidi, S, Pencavel, T, Kyula, JN, White, C, McLaughlin, M, Seth, R, Karapanagiotou, EM, Mansfield, D, Coffey, M, Nuovo, G, Vile, RG, Pandha, HS, Melcher, AA, Harrington, KJ
Publicado no Gene Ther (2012)